Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies

International Journal of Radiation Oncology, Biology, Physics, Volume 99, Issue 5, 2017 Dec 1 | Welsh, J.W.; Tang, C.; de Groot, P.;...
Purpose/Objective(s) We present early toxicity and efficacy findings from a phase 2 trial that combines CTLA4 blockade (ipilimumab) with stereotactic ablative radiation therapy (SABRacrnm1) targeting metastatic lung or liver lesions in patients wi...

http://ift.tt/2AYiF70